These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19924060)

  • 21. Prediction of transdermal flux of prodrugs of 5-fluorouracil, theophylline, and 6-mercaptopurine with a series/parallel model.
    Roberts WJ; Sloan KB
    J Pharm Sci; 2000 Nov; 89(11):1415-31. PubMed ID: 11015687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-Alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) prodrugs of carboxylic acid containing drugs.
    Majumdar S; Sloan KB
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1447-50. PubMed ID: 17196386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of aqueous and lipid solubilities with flux for prodrugs of 5-fluorouracil, theophylline, and 6-mercaptopurine: A Potts-Guy approach.
    Roberts WJ; Sloan KB
    J Pharm Sci; 1999 May; 88(5):515-22. PubMed ID: 10229642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of acetaminophen proline prodrug.
    Wu Z; Patel A; Dave R; Yuan X
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3851-4. PubMed ID: 20627561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of water solubility of solutes on their flux through human skin in vitro: a prodrug database integrated into the extended Flynn database.
    Juntunen J; Majumdar S; Sloan KB
    Int J Pharm; 2008 Mar; 351(1-2):92-103. PubMed ID: 18023303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-Mannich-base prodrugs of 5-iodo-2'-deoxycytidine as topical delivery enhancers.
    Koch SA; Sloan KB
    Pharm Res; 1987 Aug; 4(4):317-20. PubMed ID: 3508538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling of flux through silicone membranes from water.
    Wasdo S; Juntunen J; Devarajan H; Murray T; Nickels D; Singh S; Shanks T; Ulmer K; Sloan KB
    Eur J Pharm Sci; 2008 Aug; 34(4-5):321-32. PubMed ID: 18588972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced delivery of zidovudine through rat and human skin via ester prodrugs.
    Seki T; Kawaguchi T; Juni K
    Pharm Res; 1990 Sep; 7(9):948-52. PubMed ID: 2235895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and evaluation of Ketorolac ester prodrugs for transdermal delivery.
    Doh HJ; Cho WJ; Yong CS; Choi HG; Kim JS; Lee CH; Kim DD
    J Pharm Sci; 2003 May; 92(5):1008-17. PubMed ID: 12712420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of vehicles and prodrug properties and their interactions on the delivery of 6-mercaptopurine through skin: bisacyloxymethyl-6-mercaptopurine prodrugs.
    Waranis RP; Sloan KB
    J Pharm Sci; 1987 Aug; 76(8):587-95. PubMed ID: 11002816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microemulsions as topical delivery vehicles for the anti-melanoma prodrug, temozolomide hexyl ester (TMZA-HE).
    Suppasansatorn P; Nimmannit U; Conway BR; Du L; Wang Y
    J Pharm Pharmacol; 2007 Jun; 59(6):787-94. PubMed ID: 17637171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prodrugs for transdermal drug delivery - trends and challenges.
    Ita KB
    J Drug Target; 2016 Sep; 24(8):671-8. PubMed ID: 26878159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of vehicles and prodrug properties and their interactions on the delivery of 6-mercaptopurine through skin: S6-acyloxymethyl-6-mercaptopurine prodrugs.
    Waranis RP; Sloan KB
    J Pharm Sci; 1988 Mar; 77(3):210-5. PubMed ID: 3373424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of ester promoieties on transdermal delivery of ketorolac.
    Liu KS; Hsieh PW; Aljuffali IA; Lin YK; Chang SH; Wang JJ; Fang JY
    J Pharm Sci; 2014 Mar; 103(3):974-86. PubMed ID: 24481782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of piperazinylalkyl ester prodrugs of ketorolac and their in vitro evaluation for transdermal delivery.
    Qandil A; Al-Nabulsi S; Al-Taani B; Tashtoush B
    Drug Dev Ind Pharm; 2008 Oct; 34(10):1054-63. PubMed ID: 18608464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design for optimized topical delivery: Prodrugs and a paradigm change.
    Sloan KB; Wasdo SC; Rautio J
    Pharm Res; 2006 Dec; 23(12):2729-47. PubMed ID: 17109215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ester prodrugs of morphine improve transdermal drug delivery: a mechanistic study.
    Wang JJ; Sung KC; Huang JF; Yeh CH; Fang JY
    J Pharm Pharmacol; 2007 Jul; 59(7):917-25. PubMed ID: 17637185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ionized prodrugs of dehydroepiandrosterone for transdermal iontophoretic delivery.
    Laneri S; Sacchi A; di Frassello EA; Luraschi E; Colombo P; Santi P
    Pharm Res; 1999 Dec; 16(12):1818-24. PubMed ID: 10644068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone.
    Mäntylä A; Garnier T; Rautio J; Nevalainen T; Vepsälainen J; Koskinen A; Croft SL; Järvinen T
    J Med Chem; 2004 Jan; 47(1):188-95. PubMed ID: 14695832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of transdermal apomorphine delivery with a diester prodrug strategy.
    Liu KS; Sung KC; Al-Suwayeh SA; Ku MC; Chu CC; Wang JJ; Fang JY
    Eur J Pharm Biopharm; 2011 Aug; 78(3):422-31. PubMed ID: 21315820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.